Is Chlorpheniramine Maleate Safe During Pregnancy?

Chlorpheniramine maleate is an older antihistamine that many clinicians consider an option for allergy and cold symptoms during pregnancy, but it is not risk-free and it is not a first choice for everyone. The main concern is that it can cause drowsiness and, in some cases, has been linked to a small increase in certain birth defects when used in early pregnancy. Most health authorities do not classify it as a proven cause of birth defects. If you are pregnant and considering it, talk to your clinician before taking it rather than deciding on your own.

What Is Chlorpheniramine Maleate?

Chlorpheniramine maleate is a first-generation antihistamine. It blocks histamine, the chemical your body releases during allergic reactions. That makes it useful for sneezing, runny nose, itchy eyes, and hives.

It is sold under many brand names and is also common in combination cold and allergy products. It is available over the counter in the United States, which is part of why people assume it must be safe for everyone. Over-the-counter status means a product met regulatory standards for sale. It does not mean the product has been proven safe in pregnancy.

This drug belongs to the same broad class as diphenhydramine (Benadryl) and doxylamine. A defining feature of first-generation antihistamines is that they cross into the brain and cause sedation. That drowsiness is the most common side effect, and it matters during pregnancy for practical reasons like driving and work.

Is Chlorpheniramine Maleate Safe During Pregnancy?

No major health authority has declared chlorpheniramine maleate safe for all pregnancies, and none has banned it. The honest position is that it sits in a middle zone: widely used, not clearly harmful in most studies, but carrying some signals of concern that deserve attention.

Several older antihistamines, including chlorpheniramine, have historically been treated as acceptable options by many clinicians when a pregnant patient needs allergy relief and other measures have not worked. That reflects decades of clinical use, not large modern trials. It is important to separate common practice from strong evidence. For this drug, the evidence base is older and less rigorous than what we would want today.

A meaningful share of the safety data comes from case-control studies, which compare babies with birth defects to babies without them and look back at what the mothers took. These studies can suggest associations but cannot prove cause. They are also vulnerable to recall bias, because mothers of affected babies may remember their medication use differently.

What the research generally shows is a possible small increase in risk for certain defects with early first-trimester exposure. The absolute risk remains low. A small relative increase on top of a low baseline is still a low number. That framing matters, because headlines about “increased risk” can sound far more alarming than the underlying data support.

What Does the Evidence Actually Show?

Studies on chlorpheniramine in pregnancy have produced mixed results. Some have found no meaningful increase in birth defects. Others have reported associations with specific defects, including certain heart defects and, in some analyses, eye or ear abnormalities.

These findings are not consistent across studies, and no single study is definitive. The pattern is best described as a weak signal rather than a confirmed hazard. That is a genuinely different situation from a drug with a clear, replicated pattern of harm.

One clarification worth knowing: the drug’s pregnancy risk category system that many people remember from older labeling has been phased out in the United States. The replacement is a narrative section in the prescribing information that describes what is and is not known. For chlorpheniramine, that narrative reflects exactly this uncertainty, not a clean bill of health.

There is also limited data on use later in pregnancy. Near delivery, first-generation antihistamines can affect the newborn, and some clinicians advise against heavy use close to term. This is a clinical judgment area where guidance varies.

Why Antihistamines Get Extra Scrutiny in Pregnancy

The first trimester is when major organs form. That window, roughly the first 12 weeks, is when medication exposure carries the most theoretical concern for structural birth defects. It is also when many people do not yet know they are pregnant, which is why unintended early exposure is common.

Antihistamines cross the placenta to some degree, so the developing fetus is exposed. The question researchers try to answer is whether that exposure changes outcomes at a rate above what would happen anyway. Birth defects occur in a certain percentage of all pregnancies regardless of medication use, which makes isolating a drug’s contribution difficult.

This is why pregnancy medication questions rarely have simple yes-or-no answers. The realistic goal is to weigh the benefit of symptom relief against a small and uncertain risk, and to prefer options with the most reassuring track record when a medication is truly needed.

What Are the Alternatives for Allergy Symptoms in Pregnancy?

Not every allergy symptom needs a medication. For mild cases, reducing exposure helps. That means keeping windows closed during high-pollen periods, showering after time outdoors, and using saline nasal rinses for congestion.

When medication is needed, some antihistamines have a longer and more reassuring safety record in pregnancy than chlorpheniramine. Loratadine and cetirizine are second-generation antihistamines that cause far less drowsiness, and many clinicians consider them reasonable first choices. This is a common clinical practice rather than a conclusion from large randomized trials, and you should confirm the choice with your own clinician.

Here is a general comparison of the main options people ask about. It is not a recommendation, and dosing should come from your clinician or the product label.

• Chlorpheniramine: first-generation, sedating, older safety data with some mixed signals.
• Diphenhydramine: first-generation, sedating, widely used but also carries sedation concerns.
• Loratadine and cetirizine: second-generation, much less sedating, generally favored when an antihistamine is needed.
• Saline rinses and avoidance: no drug exposure, useful for mild nasal symptoms.

For congestion specifically, some clinicians prefer treatments other than oral decongestants during pregnancy. Decongestants are a separate category with their own safety questions, so do not assume a combination cold product is a safer choice just because it is familiar.

What Should You Do If You Have Already Taken It?

Do not panic. Many people take chlorpheniramine before they know they are pregnant, and the vast majority have healthy pregnancies. The reported associations are small and uncertain, not a sign that harm has occurred.

Tell your clinician what you took, how much, and when. That information helps them decide whether any extra monitoring is warranted. In most cases, routine prenatal care continues as normal.

Going forward, the practical step is to check with your clinician or pharmacist before starting any over-the-counter cold or allergy product. Many contain more than one active ingredient, and labels do not always make the pregnancy considerations obvious. Some products combine an antihistamine with a decongestant, a pain reliever, or a cough suppressant, each with its own questions.

If your symptoms are severe, persistent, or affecting sleep and daily life, that is worth raising too. Uncontrolled symptoms are their own problem, and the goal is a plan that manages them with the least unnecessary risk.